PMID: 12777271Jun 5, 2003Paper

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

The American Journal of Psychiatry
John M KaneKeith Karcher

Abstract

The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. In a 12-week, multicenter, double-blind, randomized study, patients received intramuscular injections every 2 weeks of placebo or long-acting risperidone (25 mg, 50 mg, or 75 mg). The primary measure of efficacy was the change in total score on the Positive and Negative Syndrome Scale. Of the 554 patients who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline assessment. Mean changes in score of -6.2, -8.5, and -7.4 on the Positive and Negative Syndrome Scale were seen at endpoint for the 25-, 50-, and 75-mg risperidone groups, respectively; all three change scores were significantly different from that seen with placebo (+2.6). Improvements in positive and negative symptoms were also significantly greater in patients receiving risperidone. Long-acting risperidone was well tolerated. Adverse events related to extrapyramidal symptoms were spontaneously reported by 13% of patients receiving placebo and 10% of patients in the 25-mg risperidone group, with higher rates in the 50-mg and 75-mg groups. Severity of extrapyramidal symp...Continue Reading

Citations

Nov 4, 2006·Der Nervenarzt·W W Fleischhacker, W Hummer
Mar 9, 2007·Community Mental Health Journal·John P DochertyMary Kujawa
Jun 30, 2009·Advances in Therapy·David E KempRoger S McIntyre
Jul 31, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Susan D'SouzaPatrick DeLuca
May 21, 2013·Psychiatry Research·Paolo Stratta, Alessandro Rossi
Jul 13, 2004·Schizophrenia Research·Mariëlle EerdekensErik Mannaert
May 24, 2005·Schizophrenia Research·Robert A LasserJohn M Kane
Mar 12, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nadeem H BhanjiHoward C Margolese
Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David MamoDavid McDonnell
Mar 4, 2011·The New England Journal of Medicine·Robert A RosenheckUNKNOWN CSP555 Research Group
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Apr 7, 2005·International Clinical Psychopharmacology·Hans-Jürgen MöllerUNKNOWN StoRMi Study Group
Jun 4, 2005·International Clinical Psychopharmacology·Jean-Pierre LindenmayerRobert Lasser
May 17, 2006·Journal of Clinical Psychopharmacology·Jonathan RabinowitzMarielle Eerdekens
Jun 18, 2004·International Clinical Psychopharmacology·Maxine X PatelAnthony S David
Jun 18, 2004·International Clinical Psychopharmacology·Martin TurnerMariëlle Eerdekens
Jul 2, 2011·Journal of Clinical Psychopharmacology·Cheng-Tsung Liu, Ting-Hung Hsieh
Aug 11, 2007·International Clinical Psychopharmacology·A Carlo AltamuraHerbert Y Meltzer
Jan 27, 2010·International Clinical Psychopharmacology·Wayne MacfaddenJohn Thomas Haskins
Dec 1, 2004·Acta Neuropsychiatrica·Pierre S ChueJ Michael Ramstack
Sep 22, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Peter Herriot, Kamran Kheirani
Apr 25, 2006·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Tim Lambert
May 30, 2009·Diabetes, Obesity & Metabolism·Richard I G Holt, Robert C Peveler
Jul 4, 2012·Annals of General Psychiatry·Thomas R EinarsonMichiel E H Hemels
Sep 15, 2009·Clinical Interventions in Aging·Dhiren Singh, Daniel W O'Connor
Aug 9, 2011·Neuropsychiatric Disease and Treatment·Mário Rodrigues LouzãJosé Carlos Appolinário
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Michael K Rainer
Dec 4, 2003·Drugs & Aging·Prakash S Masand, Sanjay Gupta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.